Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TriLipix Approval Strengthens Abbott’s Cholesterol Franchise

Executive Summary

FDA approval of Abbott's next-generation fenofibrate TriLipix (fenofibric acid) reinforces the drug maker's position in the lucrative but maturing cholesterol market

You may also be interested in...



Abbott's Fibrate Franchise Will Likely Remain Limited To High-Risk Patients After ACCORD

Report from ACC: Experts advise reading the fine print of the study - which failed to show an overall outcome benefit - as sub-group analysis shows highest-risk patients might benefit.

AstraZeneca To Co-Promote Abbott’s TriLipix; NDA Is Filed For Crestor/TriLipix

AstraZeneca and Abbott announce co-promotion agreement for TriLipix ahead of an FDA decision on a jointly-developed investigational Crestor/TriLipix compound.

Solvay Analyzing “Various Options” For Its Pharma Unit

Belgian firm, which co-markets TriLipix and TriCor with Abbott, confirms it is in discussions with third-parties.

Related Content

UsernamePublicRestriction

Register

PS050487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel